In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $7.98.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -7.9% and a 36.03% success rate on recommended stocks.
Pharvaris has an analyst consensus of Moderate Buy, with a price target consensus of $15.75.
See Insiders’ Hot Stocks on TipRanks >>
Based on Pharvaris’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.62 million. In comparison, last year the company had a GAAP net loss of $15.2 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Read More on PHVS:
- Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium
- Pharvaris price target lowered to $20 from $25 at SVB Securities
- Pharvaris reinstated with an Outperform at JMP Securities
- Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
- Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
